Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection
This study evaluates the use of topical ABI-1968 cream, in the treatment of cervical precancerous lesions in adult women.
HSIL|HSIL of Cervix|High-Grade Squamous Intraepithelial Lesions|High-grade Cervical Intraepithelial Neoplasia|Human Papilloma Virus|Cervical Cancer|Cervical Intraepithelial Neoplasia|Cervical Neoplasm|Cervical Dysplasia|CIN
DRUG: ABI-1968
Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of cHSIL, Number of participants with Adverse Events related to treatment to determine MTD, 85 Days
Systemic exposure to Topical ABI-1968 Cream following topical application to the cervix., Plasma concentrations of ABI-1968 over time to determine systemic exposure, 85 Days|Histopathology of areas with biopsy-proven disease following multiple doses of Topical ABI-1968 Cream., Number of subjects with complete and or partial regression of cHSIL by Colposcopy and histopathology to determine change and impact over 4 weekly doses, 85 Days
This study evaluates the use of topical ABI-1968 cream, in the treatment of cervical precancerous lesions in adult women.